SCNI earnings analysis
What we found in SCNI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BiondVax reported widening operating and net losses for the quarter ended March 31, 2023: operating loss rose to $3,186 (from $2,615) and net loss to $3,515 (from $2,475). Cash and cash equivalents declined to $10,799 (from $14,075) while non-current debt (loan from others) increased to $21,851 (from $20,082). Management says existing resources plus a cost-saving plan should be adequate for at least twelve months from the filing date.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- R&D investment increased
- Research and development expense rose to $1,995 in Q1 2023 from $1,163 in Q1 2022 (increase of $832).
- Warrants liability declined materially
- Warrants liability decreased to $2,664 as of March 31, 2023 from $5,329 at December 31, 2022 (decline of $2,665); warrants revaluation of $(2,568) was recorded in cash flow adjustments.
- Equity financing closed in prior quarter
- The company completed an offering that produced gross proceeds of $8,000 and received net proceeds of $7,231 (closing December 20, 2022) providing balance sheet liquidity.
- Management expects 12-month liquidity runway
- Management states its existing resources and operating plans, including a cost saving plan, 'will be adequate to satisfy its expected liquidity requirements for a period of at least twelve months from the end of the filing date.'
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Widening net loss
- Net loss increased to $3,515 for the three months ended March 31, 2023 from $2,475 for the same period in 2022 (increase of $1,040).
- Higher operating cash burn
- Net cash used in operating activities increased to $3,059 in Q1 2023 from $1,105 in Q1 2022 (additional $1,954 of operating cash outflow).
- Cash balance declined
- Cash and cash equivalents fell to $10,799 at March 31, 2023 from $14,075 at December 31, 2022 (decline of $3,276).
- Increased loan exposure and finance expense
- Loan from others rose to $21,851 at March 31, 2023 from $20,082 at December 31, 2022 (increase of $1,769); the company recorded $1,769 of finance expenses in the quarter related to loan revaluation and paid $725 to EIB on February 16, 2023.
- Worsening shareholders' deficit
- Total shareholders' deficit worsened to $(4,810) at March 31, 2023 from $(1,760) at December 31, 2022 (deterioration of $3,050).
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.003
What they said about what is next.
The 10-Q contains no explicit numeric forward revenue or EPS guidance. Management says it plans to finance operations from existing working capital and additional sources and that its operating plans and a board-approved cost saving plan (including headcount reductions and postponing/cancelling nonessential capex) 'will be adequate' for at least twelve months from the filing date. Loan terms: maturity extended to December 31, 2027; interest accrues at 7% starting January 1, 2022 and is deferred to maturity; 10% of any capital raises will be used to repay loan principal; 3% royalties apply if sales exceed approximately $5,332 (all items disclosed in the filing).
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SCNI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever